Reactivation of hepatitis B after irinotecan

Journal of the Hong Kong College of Radiologists

Volumn 7, Issue 2, 2004, Pages 72-75

  Lui, Louisa C Y ^a   Chan, R T T ^a   Kwok, C C H ^a   Wong, W M ^a   Yau, C C ^a   Au, G K H ^a   Lai, C L ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Chemotheraphy; Hepatitis

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LAMIVUDINE; METHOTREXATE;

ADULT; ADVANCED CANCER; AGED; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG RESPONSE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; MALE; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RECURRENT INFECTION; REVIEW; VIRUS CARRIER; VIRUS REACTIVATION;

EID: 9444235152     PISSN: None     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Lok ASF, Liang RHS, Chiu EKW, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182-188.
2. Yeo W, Chan PKS, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299-307.
3. Yeo W, Chan PKS, Hui P, et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 2003;70:553-561.
4. Yeo W, Chan PKS, Ho WM, et al. Lamivudine for the preventation of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemothreapy. J Clin Oncol 2004;22:927-934.
5. Lau JY, Lai CL, Lin HJ, et al. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med 1989;73:911-917.
6. Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002;1002:391-396.
7. Lim LL, Wai CT, Lee YM, et al. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther 2002;16:1939-1944.
8. Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001;115:58-62.
9. Yeo W, Steinberg JL, Tam JS, et al. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol 1999;59:263-269.
10. Liao CA, Lee CM, Wu HC, Wang MC, Lu SN,Eng HL. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 2002;116:166-169.
11. Simpson ND, Simpson PW, Ahmed AM, et al. Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with lamivudine. J Clin Gastroenterol 2003;37: 68-71.